



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/955,174	09/19/2001	William G. Kerr	USF-T150CX	9411

23557 7590 03/20/2007  
SALIWANCHIK LLOYD & SALIWANCHIK  
A PROFESSIONAL ASSOCIATION  
PO BOX 142950  
GAINESVILLE, FL 32614-2950

EXAMINER

ZARA, JANE J

ART UNIT PAPER NUMBER

1635

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/20/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

# Office Action Summary

Application No.

09/955,174

Applicant(s)

KERR, WILLIAM G.

Examiner

Jane Zara

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 12-26-06.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 38-44, 46-66, 74-87 and 90-92 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 38-44, 46-66, 74-87 and 90-92 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>12-26-06</u> . | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

This Office action is in response to the communication filed 12-26-06.

Claims 38-44, 46-66, 74-87 and 90-92 are pending in the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

#### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed 12-26-06 has been entered.

#### ***Response to Arguments and Amendments***

##### **Withdrawn Rejections**

Any rejections not repeated in this Office action are hereby withdrawn.

##### **Maintained Rejections**

Claims 38-44, 46-66, 74-87 and 90-92 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the reasons of record set forth the Office actions mailed 5-5-05, 12-29-05 and 9-26-06, and for the

Art Unit: 1635

reasons set forth below. This is both a new matter rejection and a written description rejection, and the arguments for maintaining both grounds of rejection are set forth below.

The claims are drawn to compositions and methods for reducing SHIP-1 function in human or mouse hematopoietic cells in vivo, and for suppressing rejection of a transplant in a human or mouse comprising the administration of any interfering RNA (RNAi) specific for SHIP-1 mRNA that is present in human or mouse hematopoietic cells, which RNAi hybridizes in vitro under conditions of stringency with human or mouse SHIP-1 mRNA or hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells and reduces SHIP-1 function in human or mouse, suppresses graft-versus-host disease in a mouse or human, and suppresses transplant rejection in a human or mouse.

Applicant's arguments filed 12-26-06 have been fully considered but they are not persuasive. Applicant argues that the new matter rejection is improper because the instant application was filed after the advent of RNAi, the subject specification sets forth sufficient blaze marks to lead one of ordinary skill in the art to interfering RNA, and interfering RNA would be singled out and immediately envisioned by one of ordinary skill in the art based on the teachings of the subject specification as a whole. In support of these assertions, Applicant points out language in the instant specification that specifically mentions antisense, ribozymes and aptamers, and quotes the generic term "another genetic construct of inhibiting SHIP activity known to those of skill in the art." (see p. 11, lines 10-15 of the instant specification).

Applicant is correct that antisense, ribozymes and aptamers are specifically mentioned in the instant disclosure. There is, however, no SPECIFIC MENTION of RNAi molecules or RNAi inhibition in the original application. No examples were provided in the instant specification, either prophetic or actual, mentioning the existence of RNAi, in contrast to the mention of these other inhibitory molecules. Applicant filed an IDS on 10-7-05, well after the filing date of the original application, referencing the pioneering work by Fire, Elbashir and others concerning RNAi. These post-filing examples, however, do not provide proper support for RNAi in the application as originally filed. Post-filing amendments to the claims do not compensate for this deficiency either, as asserted previously by Applicant.

Furthermore, the declaration filed later in prosecution, on 7-21-04, provides a disclosure of experiments in which SiRNA (*a.k.a.* interfering RNA or RNAi) molecules #1, 2, 3 and 4, or a combination or subcombination of them, were found to successfully inhibit the expression of SHIP-1 in vitro and in vivo. The original application, however, does not provide disclosure of these SiRNA molecules, nor of these experiments, nor of any mention of interfering RNA molecules in general. The existence of publications, provided in the supplemental IDS (filed 10-7-05) with various references teaching RNAi molecules and their use in RNAi-mediated gene suppression in mammalian cells, does not compensate for the failure to provide support for RNAi in the original application.

Applicant argues that adequate written description has been provided for the broad genus claimed, comprising any interfering RNA (RNAi) specific for SHIP-1 mRNA that is present in human or mouse hematopoietic cells, which RNAi hybridizes in vitro

Art Unit: 1635

under conditions of stringency with human or mouse SHIP-1 mRNA or hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells and reduces SHIP-1 function in human or mouse, suppresses graft-versus-host disease in a mouse or human, and suppresses transplant rejection in a human or mouse.

Applicant argues that the disclosure at time of filing reasonably conveys to one of ordinary skill in the art that the Applicant had possession of the subject matter claimed. Applicant again refers to the teachings provided in the supplemental IDS (filed 10-7-05), citing various references teaching RNAi molecules and their use in RNAi-mediated gene suppression in mammalian cells. Applicant additionally argues that structural attributes of interfering RNA, including size and content, were known in the art at the time of filing.

Contrary to Applicant's assertions, the instant disclosure does not adequately describe the concise structural features that distinguish structures within the claimed genus from those without (e.g. the nucleotide sequences or a representative number of RNAi molecules of the generic RNAi structures claimed, that specifically bind and inhibit SHIP-1 function in vivo, and which suppress graft-versus-host disease and transplant rejection). The description provided of the target molecules claimed and the subsequent description of two RNAi constructs (filed 7-21-04) that provide for the functions claimed, of reducing SHIP-1 function in human or mouse hematopoietic cells in vivo, and of suppressing rejection of a transplant in a human or mouse, are not representative of the broad genus comprising RNAi that hybridize in vivo with SHIP-1 mRNA present in hematopoietic cells of the human or mouse and reduce SHIP-1 expression therein. The subsequent disclosure of two species within the broad genus

of RNAi molecules claimed, that, when combined provide for the treatment effects claimed, are not representative of the very broad genus of inhibitory molecules claimed.

Applicant argues that, due to the certainty of the genetic code and complementarity, there is a well-known correlation between target nucleic acid sequences within a target gene and nucleic acid sequences that interfere with the expression of the target gene.

Applicant is correct that nucleotide sequences of the target genes encoding human and mouse SHIP-1 have been reported previously, the genetic code and the existence of complementarity of gene sequences are well-known concepts. But the publication of target gene sequences, the knowledge of the existence of the genetic code and the complementarity of gene sequences together are not representative of adequate description of RNAi sequences, which sequences were adequately described and in one's possess at the time of filing, which RNAi sequences bind to and reduce SHIP-1 function in vivo, and suppress graft-versus-host disease and transplant rejection. In addition, various splice isoforms and sequence variants have been reported for mouse or human SHIP-1 (see e.g. Liu et al., Genomics, Vol. 39, pages 109-112, 1997, abstract and introduction on p. 109 and Fig. 1 on p. 110; see also Wolf et al., Genomics, Vol. 69, pages 104-112, 2000, esp. the abstract and Fig. 4 on p. 108). The specification and claims do not adequately describe the concise structural features that distinguish structures within the claimed genus from those without (e.g. the exact nucleotide sequences or a representative number of RNAi molecules of the generic

RNAi structures claimed, that specifically bind and inhibit SHIP-1 function in vivo, and which suppress graft-versus-host disease and transplant rejection).

Applicant argues that adequate written description for the broad genus of compounds claimed has been provided since the screening of RNAi candidates in vitro for their ability to target and inhibit expression of the known target gene was routine at the time of filing.

Contrary to Applicant's assertions, the ability to screen candidate inhibitory molecules for their ability to inhibit target gene inhibition in vitro is merely an invitation to experiment further to identify RNAi that exhibit inhibitory activity. The invitation to experiment does not convey possession at time of filing, and hence does not satisfy written description requirements for the broad genus of compounds claimed.

One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species of the inhibitory molecules claimed, encompassing the genus comprising RNAi specific for SHIP-1 mRNA present in human or mouse hematopoietic cells or comprising any nucleic acid molecule (and of any size) that hybridizes in vitro under conditions of stringency with human or mouse SHIP-1 mRNA or hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells and provides the treatment effects claimed. For all of these reasons, the instant 35 U.S.C. 112, first paragraph rejection, for lacking adequate written description and for failing to provide adequate support for RNAi in the originally filed application, is hereby maintained.



Claims 38-44, 46-66, 74-87 and 90-92 are rejected under 35 U.S.C. 112, first paragraph, for lacking enablement over the scope claimed for the reasons of record set forth the Office actions mailed 5-5-05, 12-29-05 and 9-26-06, and for the reasons set forth below.

The claims are drawn to methods for interfering and reducing SHIP-1 function in a human or mouse, for suppressing transplant rejection in a human or mouse, and for suppressing graft versus host disease (GVHD) in a human or mouse comprising the administration any RNAi specific for SHIP-1 mRNA present in human or mouse hematopoietic cells, or which RNAi hybridizes in vitro under conditions of stringency with human or mouse SHIP-1 mRNA or hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells.

The instant disclosure, while being enabling for a method of suppressing the rejection of an allogeneic bone marrow graft from BALB/C mice in SHIP-/- mice or abrogating GVHD disease in SHIP-/- mice that were transplanted with whole bone marrow from BALB/C mice, thereby enhancing SHIP-/- mice survival, and while being enabling for the in vivo inhibition of SHIP-1 expression in mice using the RNAi sequences #1, #4 and the mouse antisense vector muSHIPshRNA provided in the declarations by Dr. Kerr, filed 7-21-04 and 2-9-05, does not reasonably provide enablement for inhibiting SHIP-1 in vivo comprising the administration of *any* RNAi specific for SHIP-1 mRNA present in human or mouse hematopoietic cells, or comprising the administration in vivo or ex vivo of *any* nucleic acid molecule that hybridizes in vitro under conditions of stringency with human or mouse SHIP-1 mRNA

Art Unit: 1635

or that hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells, nor of suppressing a transplant rejection in any patient, or treating graft versus host disease (GVHD) in any patient comprising the administration of any interfering RNA specific for SHIP mouse or human mRNA.

Applicant's arguments filed 12-26-06 have been fully considered but they are not persuasive. Applicant argues that the full scope of the claims is enabled for several reasons. Applicant argues that the specification as filed taught the suppression of the rejection of an allogeneic bone marrow graft from BALB/C mice in SHIP-/- mice, as well as the abrogation of GVHD disease in SHIP-/- mice that were transplanted with whole bone marrow from BALB/C mice, whereby SHIP-/- mice survival was enhanced. Applicant also argues that the declarations subsequently filed on 7-21-04 and 2-9-05 taught the in vivo inhibition of SHIP-1 following the co-administration of two species of RNAi sequences, #1, #4, or following the administration of the mouse antisense vector muSHIPshRNA. Applicant also argues that prior Office actions have not stated what guidance is missing from both the subject specification and the art that is necessary to carry out the invention without resorting to undue experimentation.

Contrary to Applicant's assertions, the ability of two species of the broad genus of compounds claimed, which were co-administered RNAi's, or of the mouse antisense vector muSHIPshRNA to target and successfully inhibit expression of the target gene encoding SHIP1 in a mouse model, and provide for an observed increase in Mac+Gr1 monocytes and circulating Mac1+GR1+cells (myeloid suppressor cells) are not representative or correlative of the ability to achieve in vivo SHIP-1 inhibition of

Art Unit: 1635

expression or subsequent treatment effects comprising the administration of any RNAi specific for SHIP-1 mRNA present in human or mouse hematopoietic cells or comprising any nucleic acid molecule (and of any size) that hybridizes in vitro under conditions of stringency with human or mouse SHIP-1 mRNA or hybridizes in vivo with SHIP-1 mRNA present in mouse or human hematopoietic cells. The examples provided using three species of inhibitory molecules, are not representative, and are not enabling for the ability to provide for in vivo treatment effects claimed using the broad genus of compounds claimed.

Applicant argues further that RNAi is distinguishable from antisense and ribozymes because less RNAi are required for effective inhibition of target genes. Applicant is correct that investigators have reported that lower concentrations of RNAi molecules are likely needed for effective inhibition in a target cells compared to antisense or ribozyme molecules (see e.g. Fire (USPN 6,506,559, at col. 3). However, contrary to Applicant's assertions, while lower concentrations of RNAi molecules are likely required in target cells for effective target gene inhibition in comparison to antisense or ribozymes, in vivo efficacy of RNAi still depends on the effective delivery of threshold concentrations of these oligonucleotides sufficient to silence the target gene in target cells harboring the SHIP-1 target gene, and in vivo delivery of oligonucleotides, whether they be antisense, ribozymes or RNAi molecules, is generally a highly unpredictable endeavor at the current time.

Caplen, in a recent review article concerning RNAi as an effective gene therapy tool (Caplen, N.J., Expert Opinion Biol. Ther., Vol. 3, No. 4, pages 575-586, 2003, esp.

Art Unit: 1635

the bridging paragraph, at pp. 577-8), addressed this unpredictability regarding predicting efficacy of RNAi molecules: "While most siRNAs are effective in inducing some degree of gene silencing, there are wide ranges in the efficacy of individual siRNAs against sequences within the same gene, and some siRNAs show limited or no ability to mediate RNAi. It is currently unclear what specific parameters determine the effectiveness of a given siRNA and, thus, why some sequences may be better targets than others." See also Caplen at p. 581: Many of the problems associated with developing RNAi as an effective therapeutic are the same as encountered with previous gene therapy approaches. The key issues of delivering nucleic acids to the required tissue and cell type, while ensuring an appropriate level of efficacy with minimum toxicity induced by the vector system have been problems the gene therapy field has struggled with for over a decade now."

Applicant additionally argues that screening for inhibitory RNAi molecules in vitro requires no undue experimentation, thereby fully enabling the claimed invention for the broad genus of compounds claimed. In addition, Applicant cites various references of success using other inhibitory molecules that target other genes to show that providing in vivo effects does not require undue experimentation. Contrary to Applicant's assertions, the success of one inhibitory molecule (e.g. whether it be antisense, ribozyme or siRNA) in vivo is not predictive of a different molecule to do the same. Testing candidate inhibitory molecules for their ability to provide treatment effects in vivo requires undue experimentation beyond that provided in the art, and in the instant disclosure. In vitro success cannot be extrapolated to in vivo efficacy, and one

Art Unit: 1635

molecule's efficacy cannot be extrapolated to another's ability to do the same.

Furthermore, the phenotypes that are obtained in ablation models do not circumvent the problems of unpredictability associated with delivery issues. Phenotypes that may be displayed in ablation models are not predictive of the ability to deliver adequate quantities of RNAi to an appropriate target cell in vivo, and provide for the treatment effects claimed. While partial suppression of SHIP expression has been shown to provide for the treatment effects instantly claimed, only two candidate RNAi molecules have been shown to provide for even partial inhibition of expression.

### ***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1635

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Douglas Schultz, can be reached on (571) 272-0763. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**Jane Zara**  
**3-13-07**

*JZ are*  
*TC 1600*  
JANE ZARA, PH.D.  
PRIMARY EXAMINER